208 related articles for article (PubMed ID: 24217470)
1. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
[TBL] [Abstract][Full Text] [Related]
2. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
3. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
[TBL] [Abstract][Full Text] [Related]
4. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
5. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
6. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.
Leard LE; Cho BK; Jones KD; Hays SR; Tope WD; Golden JA; Hoopes CW
J Heart Lung Transplant; 2007 Dec; 26(12):1340-4. PubMed ID: 18096489
[TBL] [Abstract][Full Text] [Related]
7. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE
J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
[TBL] [Abstract][Full Text] [Related]
8. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; Martín P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
11. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.
Borradori L; Sutton B; Shayesteh P; Daniels GA
Br J Dermatol; 2016 Dec; 175(6):1382-1386. PubMed ID: 27059424
[No Abstract] [Full Text] [Related]
12. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Gaffney DC; Soyer HP; Simpson F
Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
[TBL] [Abstract][Full Text] [Related]
13. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Jalili A; Pinc A; Pieczkowski F; Karlhofer FM; Stingl G; Wagner SN
J Dtsch Dermatol Ges; 2008 Dec; 6(12):1066-9. PubMed ID: 19138272
[TBL] [Abstract][Full Text] [Related]
14. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Saba NF; Khuri FR; Shin DM
Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
Bauman JE; Eaton KD; Martins RG
Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
[TBL] [Abstract][Full Text] [Related]
16. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
17. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
[No Abstract] [Full Text] [Related]
18. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab.
Suen JK; Bressler L; Shord SS; Warso M; Villano JL
Anticancer Drugs; 2007 Aug; 18(7):827-9. PubMed ID: 17581306
[TBL] [Abstract][Full Text] [Related]
19. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
Lartigau EF; Tresch E; Thariat J; Graff P; Coche-Dequeant B; Benezery K; Schiappacasse L; Degardin M; Bondiau PY; Peiffert D; Lefebvre JL; Lacornerie T; Kramar A
Radiother Oncol; 2013 Nov; 109(2):281-5. PubMed ID: 24262821
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]